Business Context and Reporting Period
This Form 8-K Current Report was filed by Minerva Neurosciences, Inc. on November 14, 2025, with a signature date of November 19, 2025. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the execution of a related consulting agreement, pursuant to a securities purchase agreement entered into on October 21, 2025.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to specific compensation arrangements for a new director:
- Director Cash Retainer: $40,000 annually (prorated for the remainder of 2025).
- Director Equity Grant: Initial option to purchase 9,500 shares of common stock, vesting quarterly over three years.
- Consulting Fee: $450 per hour for approximately 25 to 30 hours per month.
- Consulting Equity Grant: Option to purchase shares representing 0.7% of the "Share Total" (subject to Board and stockholder approval of share reserve increases).
Material Changes
The filing reports the following material changes to the Company's governance and personnel structure:
- Board Expansion: The Board of Directors increased its size to six (6) members.
- Director Appointment: Inderjit Kaul, M.D., MPH, was appointed as a Class II director. His initial term expires at the 2025 Annual Meeting of Stockholders.
- Consulting Engagement: A six-month initial consulting agreement was executed with Dr. Kaul to assist with clinical trial workstreams, with an option to renew.
Outlook, Risks, and Unusual Items
Management Commentary and Milestones: The consulting agreement includes performance-based equity vesting tied to specific clinical milestones for the Company's Phase 3 confirmatory trial of roluperidone in schizophrenia:
- 25% Vesting: After one year of continuous service.
- 45% Vesting: Upon public announcement of achieving the primary endpoint at the 12-week timepoint on a statistically significant basis.
- 30% Vesting: Upon public announcement of safety data from the 40-week relapse assessment phase.
Risks and Contingencies: The consulting agreement may be terminated by either party with 30 days' notice, or immediately by the Company for material breach. The equity grant under the consulting agreement is contingent upon stockholder approval of an increase to the share reserve under the Company's Equity Incentive Plan.
Investor Verification Checklist
- Verify the status of the stockholder vote required to increase the share reserve for the 0.7% consultant option grant.
- Confirm the specific vesting schedule and conditions for the 9,500 director option shares.
- Monitor upcoming clinical trial announcements regarding the Phase 3 roluperidone trial (12-week primary endpoint and 40-week safety data) which trigger significant equity vesting.
- Review the full text of the Consulting Agreement (Exhibit 10.1) for detailed terms regarding the "Share Total" definition and top-up option mechanics.